Literature DB >> 1708255

Metabolism of substance P and bradykinin by human neutrophils.

R A Skidgel1, H L Jackman, E G Erdös.   

Abstract

The catabolism of substance P and bradykinin, two peptides involved in inflammation, by human neutrophils was investigated. Substance P was cleaved by unstimulated neutrophils, but the rate of hydrolysis increased greatly (about 4-fold) when the cells were lysed by freezing and thawing or stimulated to release with fMet-Leu-Phe and cytochalasin B. The enzyme responsible for cleaving substance P was cathepsin G, hydrolyzing the Phe7-Phe8 bond. Neutral endopeptidase 24.11 (enkephalinase) became the main inactivating enzyme only when neutrophil cytoplasts (containing plasma membrane but no subcellular particles) or washed plasma membrane enriched high speed sediments were tested. Subcellular fractionation showed the highest substance P degrading activity to be in the granules. Purified cathepsin G readily cleaved substance P with a Km of 1.13 MK, a kcat of 6.35 sec-1 and a kcat/Km of 5639 M-1 sec-1, similar to kinetic constants previously reported for the best peptide substrates of cathepsin G. Despite the high Km, purified cathepsin G did hydrolyze SP at a much lower substrate concentration (down to 1 nM) as determined by radioimmunoassay. Bradykinin was also hydrolyzed by intact neutrophils but, in contrast, was not inactivated by cathepsin G, but by neutral endopeptidase at the Pro7-Phe8 bond. The inactivation of bradykinin by intact neutrophils was decreased by phorbol 12-myristate 13-acetate, probably due to down-regulation by endocytosis of the neutral endopeptidase on the plasma membrane. Thus, both bradykinin and substance P are inactivated by human neutrophils, although by different enzymes. In spite of the less favorable kinetics in vitro than with neutral endopeptidase, cathepsin G is the main inactivator of substance P in neutrophils. This may be due to the estimated 300 to 3600-fold higher concentration of cathepsin G in neutrophils than that of the neutral endopeptidase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708255     DOI: 10.1016/0006-2952(91)90106-f

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  The significance of substance P in physiological and malignant haematopoiesis.

Authors:  Michal Nowicki; Danuta Ostalska-Nowicka; Beata Kondraciuk; Bogdan Miskowiak
Journal:  J Clin Pathol       Date:  2006-12-15       Impact factor: 3.411

Review 2.  New aspects of melanocortin signaling: a role for PRCP in α-MSH degradation.

Authors:  Sabrina Diano
Journal:  Front Neuroendocrinol       Date:  2010-10-25       Impact factor: 8.606

Review 3.  Pathologic consequences of increased angiotensin II activity.

Authors:  C M Ferrario; J M Flack
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

4.  The substance P fragment SP-(7-11) increases prostaglandin E2, intracellular Ca2+ and collagenase production in bovine articular chondrocytes.

Authors:  D A Halliday; J D McNeil; W H Betts; R Scicchitano
Journal:  Biochem J       Date:  1993-05-15       Impact factor: 3.857

5.  Activation of human neutrophils by tachykinins: effect on formyl-methionyl-leucyl-phenylalanine- and platelet-activating factor-stimulated superoxide anion production and antibody-dependent cell-mediated cytotoxicity.

Authors:  A Wozniak; W H Betts; G McLennan; R Scicchitano
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

6.  Effect of substance P on superoxide anion and IL-8 production by human PMNL.

Authors:  M C Serra; F Calzetti; M Ceska; M A Cassatella
Journal:  Immunology       Date:  1994-05       Impact factor: 7.397

7.  Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophils-induced endothelial cytotoxity.

Authors:  T Matsumura; K Kugiyama; S Sugiyama; M Ohgushi; K Amanaka; M Suzuki; H Yasue
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

Review 8.  The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy.

Authors:  Agnieszka Majkowska-Pilip; Paweł Krzysztof Halik; Ewa Gniazdowska
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.